This Firm Just Registered a 10 on the Valuentum Buying Index
publication date: Aug 31, 2014
This firm's new treatment has a high rate of effectiveness, and its lack of competition has fueled rapid adoption in the medical community. This firm has so much monopolistic power that Congress is complaining that it is putting too much budgetary pressure on Medicare and Medicaid. The company just registered the highest rating of a 10 on the Valuentum Buying Index (equivalent to a "we'd consider buying" rating), and we think there is considerable share-price upside. The stock not only trades at a material discount to its discounted cash-flow-derived intrinsic value, but its earnings multiple is but a fraction of its peer group's.
To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.